Because abnormal Tau aggregation is linked to the pathogenesis of many neurodegenerative diseases [2–5], there is escalating interest in understanding the mechanism of clearance and degradation of Tau aggregates for better management of related tauopathies. This evidence concerns the gene MAPT and neurodegenerative disease.